CVRx (CVRX) Expected to Announce Quarterly Earnings on Thursday

CVRx (NASDAQ:CVRX) is projected to announce its earnings results before the market opens on Thursday, January 23rd. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $14,850.00 billion for the quarter. CVRx has set its Q4 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). The firm had revenue of $13.37 million for the quarter, compared to analyst estimates of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same period in the previous year, the firm earned ($0.43) earnings per share. On average, analysts expect CVRx to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Performance

CVRX opened at $18.40 on Wednesday. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. The business’s 50 day moving average is $14.21 and its 200-day moving average is $11.20. The stock has a market cap of $446.38 million, a PE ratio of -6.81 and a beta of 1.26. CVRx has a twelve month low of $6.40 and a twelve month high of $29.23.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. William Blair upgraded CVRx from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 14th. Lake Street Capital upped their price objective on shares of CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $14.00 target price on shares of CVRx in a research note on Wednesday, October 23rd. Craig Hallum boosted their price target on shares of CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of CVRx in a report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.